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Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the health problems with great burden on the liver
that may end with liver cirrhosis and hepatocellular carcinoma. The aim of this work was to assess serum vitamin D
level in nonalcoholic fatty liver disease children
Methods: This cross sectional case control study involved 47 patients with nonalcoholic fatty liver disease selected
while recruiting the pediatric hepatology clinics. Their ages ranged from 5–15 years and were compared with 23
healthy age and sex matched children. All involved patients were subjected to careful history taking, clinical
examination and for patients and control, anthropometric measures for body mass index (BMI) calculation
(plotted on WHO percentile growth charts), aspartate aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), bilirubin (total and direct), serum albumin,
creatinine, triglycerides, cholesterol, high density lipoprotein (HDL),low density lipoprotein (LDL), fasting blood
glucose and fasting insulin (for calculation of insulin resistance), C reactive protein and serum vitamin D all
were assayed. NAFLD was detected by ultrasonography and graded as absent, mild, moderate and severe.
Results: Ninety-three percent of NAFLD patients were obese. Significant differences were found between patients
and control regarding AST, ALT, ALP, GGT, total and direct bilirubin, serum albumin, creatinine, triglycerides, cholesterol,
HDL, fasting blood glucose, fasting insulin, the homeostatic model assessment for insulin resistance (HOMA-IR)
and serum vitamin D levels. Significant negative correlation was found between serum vitamin D level and
grades of steatosis.
Conclusions: Serum vitamin D level decreases in children with NAFLD. This low serum vitamin D level is associated
with higher stages of steatosis but not with BMI.
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Background
Vitamin D is a fat-soluble vitamin formed in the skin
from 7-dehydrocholestrol during exposure to solar ultra-
violet B (UVB) radiation [1]. 25-hydroxyvitamin D
[25(OH)D] is the major circulating metabolite used as
indicator of vitamin D stores [2] which is furtherly me-
tabolized in the kidneys to the biologically active form,
dihydroxy vitamin D [1,25(OH)2D]. Vitamin D deficient
individuals are more likely to develop alterations in glu-
cose metabolism as impaired glucose tolerance, meta-
bolic syndrome and type 2 diabetes mellitus [3–5].
Based on these evidences, it can be hypothesized that
vitamin D deficiency should not be considered an exclu-
sive feature of patients with osteo-mineral disorders.
Vitamin D is capable to reduce free fatty acids (FFA) in-
duced insulin resistance both in peripheral tissues and in
hepatocytes. Positive associations between 25(OH)D de-
ficiency and the prevalence of obesity have been proved.
Recent studies suggested that adequate serum 25(OH)D
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levels could be associated with increased adipocyte activ-
ity and oxidation of fat with the potential of improving
of insulin sensitivity which can lead to weight loss [6, 7].
Obese individuals tend to have lower serum vitamin D
level than those with normal weights [8, 9]. Several
mechanisms have been proposed to explain the low vita-
min D levels in obese people and include the sequestra-
tion of 25(OH)D by fat tissues as well as body size [10].
Non-alcoholic fatty liver disease (NAFLD) is defined
as the presence of steatosis in more than 5 % of hepato-
cytes in the absence of significant alcohol consumption,
drug use or hereditary diseases [11, 12]. NAFLD ranges
from simple steatosis, which involves benign fatty infil-
tration of the liver to a more severe form that involves
both steatosis and necroinflammation, known as non-
alcoholic steatohepatitis (NASH) which carries increased
risks of hepatic fibrosis and cirrhosis [13]. The preva-
lence of NAFLD had increase over the last two decades
which run paralleled the dramatic rise in childhood
obesity worldwide [14, 15].
There were no previous studies about serum vitamin
D level in the NAFLD children. The aim of this work
was to assess the vitamin D status in a group of Egyptian
children with nonalcoholic fatty liver disease.
Methods
Forty-seven patients were selected randomly from those
recruited to the pediatric hepatology outpatient clinics
in 3 Egyptian centers between Jan 2014 and May 2015
(El Sahel teaching hospital, Minia University children’s
hospital and Egyptian national liver institute). Enrolled
patients had fulfilled the following criteria: Age (5–15
years) and proved to have NAFLD by ultra-sonographic
examination. Candidates were excluded according to the
following criteria: Diagnosis of autoimmune liver disease,
positive test results for either hepatitis B surface antigen
or hepatitis C antibody, history of cardiovascular disease,
renal dysfunction, hypo or hyperthyroidism, current use
of drugs known to influence 25(OH)D metabolism in-
cluding glucocorticoids, non-steroidal anti-inflammatory
drugs and calcium/vitamin D supplements, severe dis-
ability or bone fracture, current infectious condition,
presence of tumor, severe anemia and children with
type I or II diabetes.
Another 23 healthy age and sex matched children were
included as controls selected from healthy school chil-
dren after exclusion of NAFLD (by ultra-sonographic
examination).
All the participants were subjected to detailed clinical
history taking and complete physical examination. Mea-
surements of weight (kg) and height (cm) were used to
calculate the body mass index (BMI) [=(kg/m2)]. BMI
readings were plotted on the percentile growth charts
for BMI between the age of 2 and 20 years. Childhood
obesity was defined as BMI ≥97th percentile while be-
tween 3th and 96th centile was considered normal [16].
Sampling
Five ml of venous blood were collected after an over-
night fasting in vacutainers without additive allowed to
clot for 30 min at room temperature and centrifuged at
5000 rpm for five minutes. Separated serum was stored
into aliquots at- 20 °C until biochemical analysis includ-
ing liver enzymes (ALT & AST), fasting blood glucose
(FBG), total serum cholesterol, triglyceride (TG) and
HDL cholesterol (were analyzed enzymatically using kit
obtained from Randox Laboratories Limited, Crumlin,
UK). Fasting blood glucose and fasting insulin (FINS)
was quantified by an electrochemiluminescence im-
munoassay. Insulin resistance (IR) was assessed by cal-
culating the homeostasis model assessment index for
insulin resistance (HOMA-IR) [FBG (mmol/L) × FINS
(mU/L)/22.5] [17]. C reactive protein (CRP) concentra-
tion was measured using a particle-enhanced immuno-
nephelometry. Serum vitamin D was measured by
ELISA (Immunodiagnostic Systems, Louvain-la-Neuve,
Belgium).
Liver ultrasound was performed using (GE Healthcare,
Logiq 5 pro. ultra sonogram. Real time unit with a
5 MHz abdominal transducer).
Because performing liver biopsies for the exclusive
purpose of a study is inappropriate (i.e. for assaying
25(OH)D in NAFLD children), ultra-sonographic diag-
nosis of NAFLD was made for all study participants ac-
cording to Saverymuttu et al.,1986 who graded steatosis
into four grades: 0 = absent, 1 = mild, 2 = moderate and
3 = severe [18].
The study was carried out according to the principles
of the Declaration of Helsinki, and its appendices [19]
and was approved by the hospital ethical review board in
El Sahel teaching hospital (code 114, August,2015),
Minia University hospital (code 75.a, August, 2015) and
national liver institute (code 18.c, September, 2015).
Written informed consents from the patients, caregivers
were obtained for the use of their study-related informa-
tion and for participation in the ongoing research.
Statistical analysis
The SPSS (Statistical Package for the Social Sciences)
statistical software suite, version 16.0, was used for all
statistical analyses (SPSS Inc, Chicago, IL, USA). Data
with normal distribution were expressed as the mean
values ± SD and were assessed by unpaired Student's
t-test to evaluate inter-group (NAFLD vs control) dif-
ferences. Comparative analyses of categorical variables
were carried out by the chi-square test. The relation-
ship between serum 25(OH)D and demographic and
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clinical variables were evaluated by partial correlation
testing. In addition, regression analysis was performed
to identify independent factors of NAFLD. A two-tailed
p value <0.05 indicated statistical significance.
Results
Compared to the control group, the NAFLD patients had
lower levels of serum 25(OH)D and higher values of BMI
centile, fasting blood glucose, serum triglyceride, fasting in-
sulin level, HOMA-IR, ALT, AST and GGT levels (Table 1).
Significant differences were found between patients
and controls regarding many laboratory data. Vitamin D
level is decreased in patients compared with healthy
controls (p = 0.001) (Table 2, Fig. 1).
With stratification of the studied group by grades of
steatosis (absent, mild, moderate and severe), five
(10.6 %) patients had no steatosis, 6 (12.8 %) had mild
steatosis, 17 (36.2 %) had moderate steatosis and 19
(40.4 %) had sever steatosis. Significant differences were
found between grades of steatosis regarding serum
25(OH)D except between the moderate and severe
group (p =1) (Table 2, Fig. 2).
While vitamin D level is decreased in NAFLD children,
it could not be considered as a Dependant factor in these
patients (p = 0.53) (Table 3).
Forty-nine percent (94 %) of involved patients were
obese. Despite of this, there was a non-significant
positive correlation between BMI centile and grades of
steatosis (p = 0.94).
No significant correlation between serum 25(OH)D and
age (p = 0.11, r = −0.24), BMI centile (p = 0.6, r = −0.8),
AST (p = 0.83, r = 0.03), ALT (p = 0.45, r = −0.11), GGT
(p = 0.054, r = −0.28), serum albumin (p = 0.31, r = 0.15),
total (p = 0.24, r = −0.17) and direct bilirubin (p = 0.6,
r = −0.77), serum creatinine (p = 0.69, r = 0.06), fasting glu-
cose (p = 0.16, r = −0.21) and fasting insulin levels (p =
0.72, r = −0.06), serum TG (p = 0.41, r = 0.12), serum chol-
esterol (p = 0.28, r = −0.16), LDL (p = 0.46, r = 0.11), HDL
(p = 0.57, r = −0.09) and CRP (p = 0.66, r = −0.7), HOMA-
IR (p = 0.74, r = −0.07). Significant negative correlation
was found between serum 25(OH)D and the grades of
steatosis (p <0.001, r = −0.84) (Fig. 3).
Serum 25(OH)D deficiency was not a dependent risk
factor for development of childhood nonalcoholic hepatic
Table 1 Some clinical and laboratory data of both studied groups
Parameter NAFLD patients Controls P- value
(No = 47) (No = 23)
Age Mean ± SD 11.13 ± 2.7 10.6 ± 3.1 0.43
Sex Male (%) 19 (40.4 %) 9 (39.1 %) 0.32
Female (%) 28 (59.6 %) 14 (60.9 %)
BMI centile (th) Mean ± SD 96.8723 ± 0.5 92.2 ± 9.3 <0.001*
ALT (U/L) Mean ± SD 63.8 ± 31.1 27.6 ± 5.7 <0.001*
AST (U/L) Mean ± SD 58.8 ± 22.9 28.8 ± 8.7 <0.001*
GGT (U/L) Mean ± SD 53.8 ± 21.6 34.5 ± 9.4 <0.001*
Serum albumin (mg/dl) Mean ± SD 3.5 ± 0.52 3.9 ± 0.2 <0.001*
Total bilirubin (mg/dl) Mean ± SD 1.4 ± 0.71 0.71 ± 0.2 <0.001*
Direct bilirubin (mg/dl) Mean ± SD 0.32 ± 0.2 0.14 ± 0.05 <0.001*
Alkaline phosphatase (U/L) Mean ± SD 214.4 ± 56.6 186.2 ± 46.4 0.01*
CRP (mg/dl) Mean ± SD 56 ± 18.1 5 ± 3.1 <0.001*
Serum creatinine (mg/dl) Mean ± SD 0.81 ± 0.35 1 ± 0.19 <0.001*
Serum cholesterol (mg/dl) Mean ± SD 198.3 ± 27.1 163.8 ± 27.5 <0.001*
Serum triglyceride (mg/dl) Mean ± SD 191.3 ± 37.6 157.7 ± 32.9 <0.001*
Serum LDL (mg/dl) Mean ± SD 104.7 ± 36.2 108.13 ± 11.1 0.52
Serum HDL (mg/dl) Mean ± SD 37.3 ± 9.7 43.4 ± 8.1 0.002*
Fasting Blood glucose (mg/dl) Mean ± SD 143.3 ± 33.9 100.17 ± 14.7 <0.001*
Fasting insulin (mU/ml) Mean ± SD 11.7 ± 4.8 4.5 ± 2.9 <0.001*
HOMA-IR Mean ± SD 76.6 ± 41.4 20.7 ± 16.3 <0.001
Serum 25(OH) D (nmol/L) Mean ± SD 52.1 ± 41.3 104.7 ± 36.2 <0.001*
*Significant (p value <0.05), BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma glutamyl transferase,
CRP C reactive protein, LDL Low density lipoprotein, HDL High density lipoprotein, HOMA-IR homeostasis model assessment index for insulin resistance
and 25(OH)D 25 hydroxy vitamin D
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steatosis as shown by multiple stepwise regression analysis
for the grades of steatosis (p = 0.54) (Table 3).
Discussion
To our knowledge, there is no previous study about the
level of serum vitamin D in NAFLD in children. In this
study, serum 25(OH)D was decreased compared with
controls. This comes in agreement with Targher et al.,
2007 who performed a liver biopsy to confirm NAFLD.
They found significantly lower levels of serum 25(OH)D
in NAFLD patients than in controls [20].
Obesity was found in most NAFLD children but no
significant correlation was detected between serum
25(OH)D and BMI. Excess body fat results in its
increased sequestration and low availability and, as a
consequence, low serum 25(OH) D levels [10, 21]. Fur-
ther study suggested the dilution of vitamin D in body
tissue mass (in fat cell mass as well as extracellular
fluid) rather than sequestration in the fat tissue [22].
Vitamin D dose response in obese subjects is about
30 % lower than the response in non-obese ones. In
addition, the dose–response curves in obese and non-
obese subjects are effectively parallel.
Lagunova et al. 2009 found that obese patients have
about 20 % lower levels of serum 25(OH)D compared
with normal weight or overweight persons [23].
Low serum 25(OH)D level might play a role in NAFLD
pathogenesis, possibly via suppression of its anti-
inflammatory properties. Indeed, chronic inflammation is
considered a key factor in NAFLD progression [24, 25].
Increased visceral adiposity promotes the release of both
free fatty acids and pro-inflammatory cytokines [26]. In
turn, activation of inflammation within the liver, possibly
via increased nuclear factor k B (NFkB) activity, thus pro-
moting downstream transcription of pro-inflammatory cy-
tokines and ultimately perpetuating a vicious cycle [27].
Increased levels of serum 25(OH)D might act to reduce
the development/progression of NAFLD by countering
these inflammatory processes. Lower serum 25(OH)D
levels are associated with higher circulating inflammatory
markers [28–31].
Inadequate 25(OH)D status in healthy individuals is
associated with increases in both vascular endothelial
cell NFkB protein expression and vascular NFkB signal-
ing Hence, low serum 25(OH)D levels may promote
these inflammatory processes that are also involved in
the development and progression of NAFLD [32].
A different study opposes our results supporting that
CYP27A1 and CYP2R1 enzyme expression, as well as
the ability to hydroxylize vitamin D3, are well persevered
in NASH and do not contribute to lowered serum
25(OH)D levels [33].
We found no significant correlation between BMI and
serum 25(OH)D despite of obesity in a large number of
patient. This is against Saneei et al., 2013 who proved
significant inverse weak correlation between serum
25(OH)D levels and BMI in adult populations [34].
In the present study there was inverse negative correl-
ation between vitamin D and the grades of steatosis.
Jablonski et al., 2013 proved a strong inverse relationship
between NAFLD and 25(OH)D levels [35]. Vitamin D
directly regulates the metabolism of FFAs via its action
on peroxisome proliferator-activated receptor gamma
(PPAR-γ) [36]. Studies were made to prove weather fatty
Fig. 2 Frequency of different grades of steatosis in NAFLD patients
Fig. 1 Comparison between studied and control groups regarding
serum 25(OH)D
Table 3 Univariate logistic regression analysis of serum 25(OH)D
and hepatic steatosis
Variable Odd Ratio Confidence interval (CI) p- value
Serum 25(OH)D 0.888 0.61–1.6 0.53
Table 2 Comparison between different grades of steatosis
regarding serum vitamin D level
Parameter Grade Grade Grade Grade Grade Grade All
0 & 1 0&2 0&3 1&2 1&3 2&3
p- value 0.05 <0.001* <0.001* <0.001* <0.001* 1.00 <0.001*
*Significant (p-value < 0.05)
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liver disease could be a consequence of increased inflam-
mation, or does inflammation increase hepatic steatosis.
An association between hepatic steatosis and elevation
of CRP, a protein produced predominately by the liver
under conditions of inflammation found by Ndumele
and colleagues [37]. Hepatic steatosis may exaggerate
the synthesis of high sensitivity CRP or other mediators
by the liver, thereby increasing its systemic levels. Other
laboratory studies have shown that inflammation is not a
consequence of steatosis, but could be its cause [38, 39].
Thus, in patients with NAFLD, the inflammatory re-
sponse likely functions as an amplification loop con-
tributing to hepatic steatosis.
Rhee et al., 2013 found a minor but significant diffe-
rence in 25(OH)D levels between patients with and
without NAFLD [40].
Conclusions
Serum vitamin D level decreases in children with
NAFLD. This low serum vitamin D is associated with
higher stages of steatosis but not with BMI.
Limitations of the study
1. The small number of patients included in the study
owing to the rarity of hepatic steatosis in children.
2. Liver biopsy could not be performed to either
patients or controls for accurate diagnosis of
NAFLD considering the ethics of humanity.
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